U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request Guidance for Industry and Food and Drug Administration Staff October 2017

Download the Final Guidance Document
Final
Docket Number:
FDA-2016-D-1264
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

FDA developed this guidance to clarify our position regarding manufacturers appropriately and responsibly sharing “patient-specific information” – information unique to an individual patient or unique to that patient’s treatment or diagnosis that has been recorded, stored, processed, retrieved, and/or derived from a legally marketed medical device – with that patient at that patient’s request. This guidance provides information and recommendations to industry, healthcare providers, and FDA staff about the mechanisms and considerations for device manufacturers sharing such information with individual patients when they request it.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2016-D-1264.

Back to Top